Ketamine influences CLOCK:BMAL1 function leading to altered circadian gene expression

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Bellet, Marina M ^a   Vawter, Marquis P ^a   Bunney, Blynn G ^a   Bunney, William E ^a   Sassone Corsi, Paolo ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRYPTOCHROME 1; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; KETAMINE; PER2 PROTEIN; PROTEIN BMAL1; SB 21673; TRANSCRIPTION FACTOR CLOCK; UNCLASSIFIED DRUG; AMINO ACID RECEPTOR BLOCKING AGENT; CIRCADIAN RHYTHM SIGNALING PROTEIN; CRY1 PROTEIN, MOUSE; CRYPTOCHROME; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PARP 9 PROTEIN, MOUSE; PARP-9 PROTEIN, MOUSE; PER2 PROTEIN, MOUSE;

ARTICLE; CIRCADIAN RHYTHM; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE EXPRESSION; NERVE CELL; PROMOTER REGION; TRANSCRIPTION INITIATION; ANIMAL; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; MOUSE; PHYSIOLOGY; SPECIES DIFFERENCE;

ANIMALS; CIRCADIAN RHYTHM SIGNALING PEPTIDES AND PROTEINS; CLOCK PROTEINS; CRYPTOCHROMES; EXCITATORY AMINO ACID ANTAGONISTS; GENE EXPRESSION REGULATION; KETAMINE; MICE; PERIOD CIRCADIAN PROTEINS; POLY(ADP-RIBOSE) POLYMERASES; SPECIES SPECIFICITY;

EID: 80051988901     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023982     Document Type: Article

References (75)

1. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE, (2005) Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62: 617-627.
2. NIMH (2011) Any Mood Disorder Among Adults (http://wwwapps.nimh.nih.gov/health/publications/the-numbers-count-mental-disorders-in-america.shtml).
3. Gelenberg AJ, Chesen CL, (2000) How fast are antidepressants? J Clin Psychiatry 61: 712-721.
4. Jick H, Kae JA, Jick SS, (2004) Antidepressants and the risk of suicidal behaviors. JAMA 292: 338-343.
5. Rush AJ, Trivedi M, Fava M, (2003) Depression, IV: STAR*D treatment trial for depression. Am J Psychiatry 160: 237.
6. Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR, (2007) The STAR*D Project results: a comprehensive review of findings. Curr Psychiatry Rep 9: 449-459.
7. Maeng S, Zarate CA Jr, Du J, Schloesser RJ, McCammon J, et al. (2008) Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 63: 349-352.
8. Bunney BG, Bunney WE, (2011) Rapid-acting antidepressant strategies: mechanisms of action. International Journal Neuropsychopharmacology 7: 1-19.
9. Zarate C Jr, Machado-Vieira R, Henter I, Ibrahim L, Diazgranados N, et al. (2010) Glutamatergic modulators: the future of treating mood disorders? Harv Rev Psychiatry 18: 293-303.
10. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, et al. (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63: 856-864.
11. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, et al. (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47: 351-354.
12. aan het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, et al. (2010) Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 67: 139-145.
13. Price RB, Nock MK, Charney DS, Mathew SJ, (2009) Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 66: 522-526.
14. Colwell CS, Menaker M, (1992) NMDA as well as non-NMDA receptor antagonists can prevent the phase-shifting effects of light on the circadian system of the golden hamster. J Biol Rhythms 7: 125-136.
15. Paul KN, Fukuhara C, Karom M, Tosini G, Albers HE, (2005) AMPA/kainate receptor antagonist DNQX blocks the acute increase of Per2 mRNA levels in most but not all areas of the SCN. Brain Res Mol Brain Res 139: 129-136.
16. Paul KN, Fukuhara C, Tosini G, Albers HE, (2003) Transduction of light in the suprachiasmatic nucleus: evidence for two different neurochemical cascades regulating the levels of Per1 mRNA and pineal melatonin. Neuroscience 119: 137-144.
17. Abe H, Rusak B, Robertson HA, (1992) NMDA and non-NMDA receptor antagonists inhibit photic induction of Fos protein in the hamster suprachiasmatic nucleus. Brain Res Bull 28: 831-835.
18. Chambille I, (1999) Circadian rhythm of AMPA receptor GluR2/3 subunit-immunoreactivity in the suprachiasmatic nuclei of Syrian hamster and effect of a light-dark cycle. Brain Res 833: 27-38.
19. Ishida N, Matsui M, Mitsui Y, Mishina M, (1994) Circadian expression of NMDA receptor mRNAs, epsilon 3 and zeta 1, in the suprachiasmatic nucleus of rat brain. Neurosci Lett 166: 211-215.
20. Sato Y, Kobayashi E, Hakamata Y, Kobahashi M, Wainai T, et al. (2004) Chronopharmacological studies of ketamine in normal and NMDA epsilon1 receptor knockout mice. Br J Anaesth 92: 859-864.
21. Chassard D, Duflo F, de Queiroz Siqueira M, Allaouchiche B, Boselli E, (2007) Chronobiology and anaesthesia. Curr Opin Anaesthesiol 20: 186-190.
22. Bunney JN, Potkin SG, (2008) Circadian abnormalities, molecular clock genes and chronobiological treatments in depression. Br Med Bull 86: 23-32.
23. Bunney WE, Bunney BG, (2000) Molecular clock genes in man and lower animals: possible implications for circadian abnormalities in depression. Neuropsychopharmacology 22: 335-345.
24. Morris DW, Trivedi MH, Fava M, Wisniewski SR, Balasubramani GK, et al. (2009) Diurnal mood variation in outpatients with major depressive disorder. Depress Anxiety 26: 851-863.
25. Wirz-Justice A, (2008) Diurnal variation of depressive symptoms. Dialogues Clin Neurosci 10: 337-343.
26. Lam RW, (2006) Sleep disturbances and depression: a challenge for antidepressants. Int Clin Psychopharmacol 21 (Suppl 1): S25-29.
27. Duncan WC Jr, (1996) Circadian rhythms and the pharmacology of affective illness. Pharmacol Ther 71: 253-312.
28. Rausch JL, Johnson ME, Corley KM, Hobby HM, Shendarkar N, et al. (2003) Depressed patients have higher body temperature: 5-HT transporter long promoter region effects. Neuropsychobiology 47: 120-127.
29. Nemeroff CB, (2004) Early-Life Adversity, CRF Dysregulation, and Vulnerability to Mood and Anxiety Disorders. Psychopharmacol Bull 38 (Suppl 1): 14-20.
30. Carpenter WT Jr, Bunney WE Jr, (1971) Adrenal cortical activity in depressive illness. Am J Psychiatry 128: 31-40.
31. Masri S, Sassone-Corsi P, (2010) Plasticity and specificity of the circadian epigenome. Nat Neurosci 13: 1324-1329.
32. Eckel-Mahan K, Sassone-Corsi P, (2010) Aging brains and waning clocks on the process of habituation. Aging (Albany NY) 2: 320-1.
33. Kondratova AA, Dubrovsky YV, Antoch MP, Kondratov RV, (2010) Circadian clock proteins control adaptation to novel environment and memory formation. Aging (Albany NY) 2: 285-97.
34. Dubrovsky YV, Samsa WE, Kondratov RV, (2010) Deficiency of circadian protein CLOCK reduces lifespan and increases age-related cataract development in mice. Aging (Albany NY) 2: 936-44.
35. Vinogradova IA, Anisimov VN, Bukalev AV, Ilyukha VA, Khizhkin EA, et al. (2010) Circadian disruption induced by light-at-night accelerates aging and promotes tumorigenesis in young but not in old rats. Aging (Albany NY) 2: 82-92.
36. Krishnan N, Kretzschmar D, Rakshit K, Chow E, Giebultowicz JM, (2009) The circadian clock gene period extends healthspan in aging Drosophila melanogaster. Aging (Albany NY) 1: 937-48.
37. Bellet MM, Sassone-Corsi P, (2010) Mammalian circadian clock and metabolism- the epigenetic link. J Cell Sci 123: 3837-3848.
38. Gachon F, Bonnefont X, (2010) Circadian clock-coordinated hepatic lipid metabolism: only transcriptional regulation? Aging (Albany NY) 2: 101-6.
39. Doi M, Hirayama J, Sassone-Corsi P, (2006) Circadian regulator CLOCK is a histone acetyltransferase. Cell 125: 497-508.
40. Hirayama J, Sahar S, Grimaldi B, Tamaru T, Takamatsu K, et al. (2007) CLOCK-mediated acetylation of BMAL1 controls circadian function. Nature 450: 1086-1090.
41. Cermakian N, Sassone-Corsi P, (2000) Multilevel regulation of the circadian clock. Nat Rev Mol Cell Biol 1: 59-67.
42. Travnickova-Bendova Z, Cermakian N, Reppert SM, Sassone-Corsi P, (2002) Bimodal regulation of mPeriod promoters by CREB-dependent signaling and CLOCK/BMAL1 activity. Proc Natl Acad Sci U S A 99: 7728-7733.
43. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, et al. (2010) mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329: 959-964.
44. Cao R, Lee B, Cho HY, Saklayen S, Obrietan K, (2008) Photic regulation of the mTOR signaling pathway in the suprachiasmatic circadian clock. Mol Cell Neurosci 38: 312-324.
45. Cao R, Li A, Cho HY, Lee B, Obrietan K, (2010) Mammalian target of rapamycin signaling modulates photic entrainment of the suprachiasmatic circadian clock. J Neurosci 30: 6302-6314.
46. Gekakis N, Staknis D, Nguyen HB, Davis FC, Wilsbacher LD, et al. (1998) Role of the CLOCK protein in the mammalian circadian mechanism. Science 280: 1564-1569.
47. Yujnovsky I, Hirayama J, Doi M, Borrelli E, Sassone-Corsi P, (2006) Signaling mediated by the dopamine D2 receptor potentiates circadian regulation by CLOCK:BMAL1. Proc Natl Acad Sci U S A 103: 6386-6391.
48. Doi M, Yujnovsky I, Hirayama J, Malerba M, Tirotta E, et al. (2006) Impaired light masking in dopamine D2 receptor-null mice. Nature Neurosc 9: 732-734.
49. Li CY, Chou TC, Wong CS, Ho ST, Wu CC, et al. (1997) Ketamine inhibits nitric oxide synthase in lipopolysaccharide-treated rat alveolar macrophages. Can J Anaesth 44: 989-95.
50. Chan PH, Chu L, (1990) Mechanisms underlying glutamate-induced swelling of astrocytes in primary culture. Acta Neurochir Suppl (Wien) 51: 7-10.
51. Weiss J, Goldberg MP, Choi DW, (1986) Ketamine protects cultured neocortical neurons from hypoxic injury. Brain Res 380: 186-90.
52. Chang Y, Lee JJ, Hsieh CY, Hsiao G, Chou DS, et al. (2009) Inhibitory effects of ketamine on lipopolysaccharide-induced microglial activation. Mediators Inflamm.
53. Chang Y, Chen TL, Wu GJ, Hsiao G, Shen MY, et al. (2004) Mechanisms involved in the antiplatelet activity of ketamine in human platelets. J Biomed Sci 11 (6): 764-72.
54. Harada Y, Sakai M, Kurabayashi N, Hirota T, Fukada Y, (2005) Ser-557-phosphorylatedmCRY2 is degraded upon synergistic phosphorylation by glycogen synthase kinase-3 beta. J Biol Chem 280: 31714-31721.
55. Iitaka C, Miyazaki K, Akaike T, Ishida N, (2005) A role for glycogen synthase kinase-3beta in the mammalian circadian clock. J Biol Chem 280: 29397-29402.
56. Spengler ML, Kuropatwinski KK, Schumer M, Antoch MP, (2009) A serine cluster mediates BMAL1-dependent CLOCK phosphorylation and degradation. Cell Cycle 8: 4138-4146.
57. Sahar S, Zocchi L, Kinoshita C, Borrelli E, Sassone-Corsi P, (2010) Regulation of BMAL1 protein stability and circadian function by GSK3beta-mediated phosphorylation. PLoS One 5: e8561.
58. Yin L, Wang J, Klein PS, Lazar MA, (2006) Nuclear receptor Rev-erbalpha is a critical lithium-sensitive component of the circadian clock. Science 311: 1002-1005.
59. Doble BW, Woodgett JR, (2003) GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 116: 1175-1186.
60. Machado-Vieira R, Salvadore G, DiazGranados N, Ibrahim L, Latov D, et al. (2010) New therapeutic targets for mood disorders. Scientific World Journal 10: 713-726.
61. Nakahata Y, Kaluzova M, Grimaldi B, Sahar S, Hirayama J, et al. (2008) The NAD+-dependent deacetylase SIRT1 modulates CLOCK-mediated chromatin remodeling and circadian control. Cell 134: 329-340.
62. Tamanini F, (2007) Manipulation of mammalian cell lines for circadian studies. Methods MolBiol 362: 443-453.
63. Bain J, Plater L, Elliott M, Shapiro N, Hastie CJ, et al. (2007) The selectivity of protein kinase inhibitors: a further update. Biochem J 408: 297-315.
64. Abe M, Herzog ED, Block GD, (2000) Lithium lengthens the circadian period of individual suprachiasmatic nucleus neurons. Neuroreport 11: 3261-3264.
65. Gould TD, Manji HK, (2005) Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology 30: 1223-1237.
66. Beurel E, Song L, Jope RS, (2011) Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice. Mol Psychiatry 19: 1-2.
67. Asai M, Yamaguchi S, Isejima H, Jonouchi M, Moriya T, et al. (2001) Visualization of mPer1 transcription in vitro: NMDA induces a rapid phase shift of mPer1 gene in cultured SCN. Curr Biol 11: 1524-1527.
68. Skerry TM, Genever PG, (2001) Glutamate signalling in non-neuronal tissues. Trends Pharmacol Sci 22: 174-81.
69. Genever PG, Maxfield SJ, Kennovin GD, Maltman J, Bowgen CJ, et al. (1999) Evidence for a novel glutamate-mediated signaling pathway in keratinocytes. J Invest Dermatol 112: 337-42.
70. Genever PG, Wilkinson DJ, Patton AJ, Peet NM, Hong Y, et al. (1999) Expression of a functional N-methyl-D-aspartate-type glutamate receptor by bone marrow megakaryocytes. Blood 93: 2876-83.
71. Peet NM, Grabowski PS, Laketic-Ljubojevic I, Skerry TM, (1999) The glutamate receptor antagonist MK801 modulates bone resorption in vitro by a mechanism predominantly involving osteoclast differentiation. Faseb J 13: 2179-85.
72. Shang LH, Luo ZQ, Deng XD, Wang MJ, Huang FR, et al. (2010) Expression of N-methyl-D-aspartate receptor and its effect on nitric oxide production of rat alveolar macrophages. Nitric Oxide 23: 327-31.
73. Roybal K, Theobold D, Graham A, DiNieri JA, Russo SJ, et al. (2007) Mania-like behavior induced by disruption of CLOCK. Proc Natl Acad Sci U S A 104: 6406-6411.
74. Cardone L, Hirayama J, Giordano F, Tamaru T, Palvimo JJ, et al. (2005) Circadian clock control by SUMOylation of BMAL1. Science 309: 1390-1394.
75. Nowak DE, Tian B, Brasier AR, (2005) Two-step cross-linking method for identification of NF-kappaB gene network by chromatin immunoprecipitation. Biotechniques 39: 715-725.